Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy

Bañez, Lionel L.; Sun, Leon; Trock, Bruce J.; Han, Misop; Partin, Alan W.; Aronson, William J.; Terris, Martha K.; Presti, Joseph C.; Kane, Christopher J.; Amling, Christopher L.; Moul, Judd W.; Freedland, Stephen J.

doi:10.1016/j.juro.2009.04.007

« Previous Next »The Journal of Urology
Volume 182, Issue 2 , Pages 491-498, August 2009

Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy

Lionel L. Bañez
- Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
- Urology Section, Veterans Affairs Medical Center, Durham, North Carolina
- Correspondence: Division of Urologic Surgery and Duke Prostate Center, and Department of Surgery, Duke University Medical Center, Box 2626, MSRB-I, Suite 455, 571 Research Dr., Durham, North Carolina 27710 (telephone: 919-668-8449; FAX: 919-668-7093)
- Financial interest and/or other relationship with AstraZeneca.
Leon Sun
- Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
Bruce J. Trock
- Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
Misop Han
- Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
Alan W. Partin
- Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
William J. Aronson
- Urology Section, Veterans Affairs Greater Los Angeles Healthcare System and Department of Urology, University of California Los Angeles School of Medicine, Los Angeles, California
Martha K. Terris
- Urology Section, Veterans Affairs Medical Center, Augusta and Section of Urology, Medical College of Georgia, Augusta, Alabama
Joseph C. Presti Jr
- Urology Section, Veterans Affairs Medical Center and Department of Urology, Stanford University School of Medicine, Palo Alto, California
Christopher J. Kane
- Urology Section, Veterans Affairs Medical Center, San Diego and Department of Urology, University of California San Diego, San Diego, California
Christopher L. Amling
- Urology Section, Veterans Affairs Medical Center, and Department of Urology, University of Alabama, Birmingham, Alabama
Judd W. Moul
- Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
- Financial interest and/or other relationship with Sanofi-Aventis, AstraZeneca and GlaxoSmithKline.
Stephen J. Freedland
- Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
- Department of Pathology, Duke University Medical Center, Durham, North Carolina
- Urology Section, Veterans Affairs Medical Center, Durham, North Carolina

Received 19 November 2008 published online 15 June 2009.

To access this article, please choose from the options below

Study received institutional review board approval at each institution.

Supported by the Department of Defense Prostate Cancer Research Program, Department of Veterans Affairs, Duke University Department of Surgery and Division of Urology, an American Urological Association Foundation/Astellas Rising Star in Urology Award, National Institutes of Health Specialized Programs of Research Excellence Grants P50 CA58236 and P50 CA92131-01A1, Georgia Cancer Coalition and National Institutes of Health R01CA100938.

PII: S0022-5347(09)00892-1

doi:10.1016/j.juro.2009.04.007

« Previous Next »The Journal of Urology
Volume 182, Issue 2 , Pages 491-498, August 2009

Access this article on SciVerse ScienceDirect